THE BANK OF NEW YORK MELLON, as Trustee THIRD SUPPLEMENTAL INDENTURE DATED as of March 12, 2015 TO THE INDENTURE DATED as of NOVEMBER 29, 2013Third Supplemental Indenture • May 8th, 2015 • Mylan N.V. • Pharmaceutical preparations • New York
Third Supplemental Indenture (this “Supplemental Indenture”), dated as of March 12, 2015, among Mylan N.V., a public limited liability company (naamloze vennootschap) organized and existing under the laws of the Netherlands (the “Parent”), Mylan Inc., a Pennsylvania corporation (the “Issuer”), and The Bank of New York Mellon, as trustee under the Indenture referred to below (the “Trustee”).
AMENDMENT NO. 1 TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 8th, 2015 • Mylan N.V. • Pharmaceutical preparations • Pennsylvania
This Amendment No. 1 to Amended and Restated Executive Employment Agreement (the “Agreement”) is entered into on April 10, 2015, to be effective as of January 1, 2015 (the “Effective Date”), by and between Mylan Inc. (the “Company”) and Anthony Mauro (“Executive”).
THE BANK OF NEW YORK MELLON, as Trustee SECOND SUPPLEMENTAL INDENTURE DATED as of March 12, 2015 TO THE INDENTURE DATED as of December 21, 2012Second Supplemental Indenture • May 8th, 2015 • Mylan N.V. • Pharmaceutical preparations • New York
Second Supplemental Indenture (this “Supplemental Indenture”), dated as of March 12, 2015, among Mylan N.V., a public limited liability company (naamloze vennootschap) organized and existing under the laws of the Netherlands (the “Parent”), Mylan Inc., a Pennsylvania corporation (the “Issuer”), and The Bank of New York Mellon, as trustee under the Indenture referred to below (the “Trustee”).
THE BANK OF NEW YORK MELLON, as Trustee FOURTH SUPPLEMENTAL INDENTURE DATED as of March 12, 2015 TO THE INDENTURE DATED as of SEPTEMBER 15, 2008Fourth Supplemental Indenture • May 8th, 2015 • Mylan N.V. • Pharmaceutical preparations • New York
Fourth Supplemental Indenture (this “Supplemental Indenture”), dated as of March 12, 2015, among Mylan N.V., a public limited liability company (naamloze vennootschap) organized and existing under the laws of the Netherlands (the “Parent”), Mylan Inc., a Pennsylvania corporation (the “Issuer”), and The Bank of New York Mellon, as trustee under the Indenture referred to below (the “Trustee”).
THE BANK OF NEW YORK MELLON, as Trustee SECOND SUPPLEMENTAL INDENTURE DATED as of March 12, 2015 TO THE INDENTURE DATED as of JUNE 25, 2013Second Supplemental Indenture • May 8th, 2015 • Mylan N.V. • Pharmaceutical preparations • New York
Second Supplemental Indenture (this “Supplemental Indenture”), dated as of March 12, 2015, among Mylan N.V., a public limited liability company (naamloze vennootschap) organized and existing under the laws of the Netherlands (the “Parent”), Mylan Inc., a Pennsylvania corporation (the “Issuer”), and The Bank of New York Mellon, as trustee under the Indenture referred to below (the “Trustee”).
THE BANK OF NEW YORK MELLON, as Trustee THIRD SUPPLEMENTAL INDENTURE DATED as of March 12, 2015 TO THE INDENTURE DATED as of May 19, 2010Third Supplemental Indenture • May 8th, 2015 • Mylan N.V. • Pharmaceutical preparations • New York
Third Supplemental Indenture (this “Supplemental Indenture”), dated as of March 12, 2015, among Mylan N.V., a public limited liability company (naamloze vennootschap) organized and existing under the laws of the Netherlands (the “Parent”), Mylan Inc., a Pennsylvania corporation (the “Issuer”), and The Bank of New York Mellon, as trustee under the Indenture referred to below (the “Trustee”).
